XML 69 R47.htm IDEA: XBRL DOCUMENT v3.25.2
SEGMENTED INFORMATION (Tables)
 12 Months Ended
Mar. 31, 2025
Disclosure of operating segments [abstract]  
Disclosure of reportable segments [Table Text Block]
    IP Development     BioTech     Albany Project     Unallocated Corporate Costs     Total  
For the year ended March 31   2025     2024     2025     2024     2025     2024     2025     2024     2025     2024  
External net sales   79,995     29,816     792,500     -     -     -     -     -     872,495     29,816  
Cost of sales   578,419     289,011     66,191     -     -     -     -     -     644,610     289,011  
Depreciation and amortization   600,322     613,714     -     -     -     -     -     -     600,322     613,714  
Interest Expense   91,323     107,373     -     -     -     -     -     -     91,323     107,373  
Net loss   (7,075,798 )   (8,368,889 )   (262,462 )   (951,877 )   (18,597 )   (508,773 )   (2,682,801 )   (1,874,451 )   (10,039,658 )   (11,703,990 )
Segment assets   10,013,831     15,217,568     828,439     8,477     7,553,915     7,359,011     -     -     18,396,185     22,585,056  
Segment liabilities   2,816,136     2,199,276     238,003     145,833     -     -     592,599     66,736     3,646,738     2,411,845  
Capital expenditures   1,398     320,099     -     -     183,214     271,857     -     -     184,612     591,956